glp-1 drug coverage As more Americans turn to drugs for weight loss, Medicare is launching a limited program to expand access for eligible beneficiaries Medicare GLP-1 Drug Coverage -

Abbreviations AIWG: Antipsychotic-induced weight gain AP(s): Antipsychotic(s) BMI: Body mass index BPRS: Brief Psychiatric Rating Scale CI: Confidence interval DM2: Diabetes mellitus type 2 ESM: Experience sampling method GLP-1: Glucagon-like peptide-1 HbA1c: Glycated haemoglobin HDL: High-density lipoprotein IRB: Institutional review board KQOL: Kemp Quality of Life scale LDL: Low-density lipoprotein MOSA: Management of Obesity with Semaglutide in AIWG NMA: Network meta-analysis QoL: Quality of life SMI: Severe mental illness UKU-SERS: UKU-Side Effect Rating Scale References van Alphen C, Ammeraal M, Blanke C, Boonstra N, Boumans H, Bruggeman R, et al

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for managing type 2 diabetes and, more recently, approved for weight management

Effect of GLP1 receptor agonists on prostate cancer risk reduction: a systematic review and metaanalysis

The drugs went into shortage back in 2022 and remained in short supply until recently

"Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (Semaglutide medicines), building on continued efforts to expand access" (Press release)

For example, the Food Science & Nutrition study on Eromion lemon extract (which we referenced in the previous section and Lemme references on its website) had less than 100 participants complete the study and lasted for 12 weeks